Zobrazeno 1 - 10
of 166
pro vyhledávání: '"Robert A, Falconer"'
Autor:
Francis M. Barnieh, Goreti Ribeiro Morais, Paul M. Loadman, Robert A. Falconer, Sherif F. El‐Khamisy
Publikováno v:
Advanced Science, Vol 11, Iss 34, Pp n/a-n/a (2024)
Abstract Targeted therapy remains the future of anti‐cancer drug development, owing to the lack of specificity of current treatments which lead to damage in healthy normal tissues. ATR inhibitors have in recent times demonstrated promising clinical
Externí odkaz:
https://doaj.org/article/89b2cd1dff6344aabd813f0ac8032b72
Autor:
Louise K. Stevenson, Amy J. Page, Matthew Dowson, Sameh K. ElBadry, Francis M. Barnieh, Robert A. Falconer, Sherif F. El-Khamisy
Publikováno v:
Frontiers in Cell and Developmental Biology, Vol 12 (2024)
Classically, ATM is known for its role in sensing double-strand DNA breaks, and subsequently signaling for their repair. Non-canonical roles of ATM include transcriptional silencing, ferroptosis, autophagy and angiogenesis. Angiogenesis mediated by A
Externí odkaz:
https://doaj.org/article/d4199569099e4c3e975aa4fb68e4854c
Autor:
Francis M. Barnieh, Sebastian P. Galuska, Paul M. Loadman, Simon Ward, Robert A. Falconer, Sherif F. El-Khamisy
Publikováno v:
iScience, Vol 26, Iss 11, Pp 108219- (2023)
Summary: Harnessing the differences between cancer and non-cancer tissues presents new opportunities for selective targeting by anti-cancer drugs. CD13, a heavily glycosylated protein, is one example with significant unmet clinical potential in cance
Externí odkaz:
https://doaj.org/article/bd2bf1908dae46818c9cada538aeea92
Publikováno v:
Advanced NanoBiomed Research, Vol 2, Iss 2, Pp n/a-n/a (2022)
Lipid nanoparticles have attracted significant interests in the last two decades, and have achieved tremendous clinical success since the first clinical approval of Doxil in 1995. At the same time, lipid nanoparticles have also demonstrated enormous
Externí odkaz:
https://doaj.org/article/684821f29d48498682b3bf0d55fd2194
Autor:
Benjamin S. Roth, Phillip Moschella, Ehsan S. Mousavi, Amanda S. LeMatty, Robert J. Falconer, Noah D. Ashley, Ali Mohammadi Nafchi, Chris Gaafary, John D. DesJardins
Publikováno v:
Journal of the American College of Emergency Physicians Open, Vol 3, Iss 1, Pp n/a-n/a (2022)
Abstract Objectives To overcome the shortage of personal protective equipment and airborne infection isolation rooms (AIIRs) in the COVID‐19 pandemic, a collaborative team of research engineers and clinical physicians worked to build a novel negati
Externí odkaz:
https://doaj.org/article/40587fed235a4012b755f11024790762
Autor:
Hayden E. Hodges, Heather J. Walker, Aaron J. Cowieson, Robert J. Falconer, Duncan D. Cameron
Publikováno v:
Frontiers in Plant Science, Vol 12 (2021)
Modern feed quality sorghum grain has been bred to reduce anti-nutrients, most conspicuously condensed tannins, but its inclusion in the diets of monogastric animals can still result in variable performance that is only partially understood. Sorghum
Externí odkaz:
https://doaj.org/article/08caa774364b4abf8757ff40da3e0256
Publikováno v:
Current Research in Pharmacology and Drug Discovery, Vol 2, Iss , Pp 100017- (2021)
The DNA damage response (DDR) is now known to play an important role in both cancer development and its treatment. Targeting proteins such as ATR (Ataxia telangiectasia mutated and Rad3-related) kinase, a major regulator of DDR, has demonstrated sign
Externí odkaz:
https://doaj.org/article/119315a7ae774e0fb0ba04253dc5fc6e
Autor:
Heike E. Daldrup-Link, Robert A. Falconer, Paul M. Loadman, Jianghong Rao, Sanjiv Sam Gambhir, Edwin Chang, Samuel Cheshier, Siddharta Mitra, Frederick T. Chin, Laura Pisani, Ketan Yerneni, Jessica Klockow, Goreti Ribeiro Morais, Kai Li, Zixin Chen, Suchismita Mohanty
Glioblastoma (GBM) has a dismal prognosis. Evidence from preclinical tumor models and human trials indicates the role of GBM-initiating cells (GIC) in GBM drug resistance. Here, we propose a new treatment option with tumor enzyme-activatable, combine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6cfde44f0d5475ce85a61715b8ac14d
https://doi.org/10.1158/1535-7163.c.6539568.v1
https://doi.org/10.1158/1535-7163.c.6539568.v1
Autor:
Heike E. Daldrup-Link, Robert A. Falconer, Paul M. Loadman, Jianghong Rao, Sanjiv Sam Gambhir, Edwin Chang, Samuel Cheshier, Siddharta Mitra, Frederick T. Chin, Laura Pisani, Ketan Yerneni, Jessica Klockow, Goreti Ribeiro Morais, Kai Li, Zixin Chen, Suchismita Mohanty
In vivo tumorigenic assay for GIC derived from pcGBM39
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3441a5004eb6b28880d2e511422ec620
https://doi.org/10.1158/1535-7163.22510302.v1
https://doi.org/10.1158/1535-7163.22510302.v1
Autor:
Jason H. Gill, Paul M. Loadman, Laurence H. Patterson, Michael C. Bibby, Steven D. Shnyder, Catherine S. Siller, Caroline J. Pennington, Dylan R. Edwards, Robert A. Falconer, Jennifer M. Atkinson
Vascular disrupting agents (VDA) offer a strategy to starve solid tumors of nutrients and oxygen concomitant with tumor shrinkage. Several VDAs have progressed into early clinical trials, but their therapeutic value seems to be compromised by systemi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0302cc92e687d673ed71302165d977e8
https://doi.org/10.1158/0008-5472.c.6501143.v1
https://doi.org/10.1158/0008-5472.c.6501143.v1